1 9 7 a r t I C l e S Glioblastoma is the most common primary brain tumor in adults with a very poor prognosis [1] [2] [3] . Treatment for GBM is maximal surgical tumor resection (debulking) 4 followed by radiation therapy, with concomitant and adjuvant chemotherapy 5, 6 . However, recurrence rates of GBM and the associated patient mortality are nearly 100%. Despite many preclinical studies, most in vivo GBM models do not mimic the clinical scenario of surgical debulking and instead focus on treating solid intact intracranial tumors. Therefore, in light of the central role of tumor resection in clinical GBM therapy, development of mouse models of GBM resection are a necessity. In this study we have first developed a mouse resection model of GBM using malignant GBM cells engineered with fluorescent and bioluminescent proteins that allow real time visualization of both growth and resection of tumors in vivo, thereby simulating the clinical scenario of GBM resection.
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Glioblastoma is the most common primary brain tumor in adults with a very poor prognosis [1] [2] [3] . Treatment for GBM is maximal surgical tumor resection (debulking) 4 followed by radiation therapy, with concomitant and adjuvant chemotherapy 5, 6 . However, recurrence rates of GBM and the associated patient mortality are nearly 100%. Despite many preclinical studies, most in vivo GBM models do not mimic the clinical scenario of surgical debulking and instead focus on treating solid intact intracranial tumors. Therefore, in light of the central role of tumor resection in clinical GBM therapy, development of mouse models of GBM resection are a necessity. In this study we have first developed a mouse resection model of GBM using malignant GBM cells engineered with fluorescent and bioluminescent proteins that allow real time visualization of both growth and resection of tumors in vivo, thereby simulating the clinical scenario of GBM resection.
Although resection of the primary tumor mass has shown clinical benefit, adjuvant chemotherapy has provided limited extra benefit 3, 6 . One of the main impediments to the efficient delivery of many therapeutic molecules is the blood brain barrier 7 and vascular dysfunction in the tumor 8 , which prevent many drugs from reaching brain tumor cells. Additionally, many drugs have short systemic half-lives and peak concentrations, which prevent drugs from ultimately reaching the brain and accumulating to therapeutic concentrations in individual brain tumor cells 9 . One of the approaches to overcome the problem of delivering drugs to intracranial tumors is to develop on-site means of delivering new tumor-specific agents. Stem cells have the ability to home to intracranial pathologies including primary and secondary tumor deposits, making them ideally suited for treatment of both primary and residual GBM cells 10 . Using tumor-specific therapeutic proteins and advanced imaging agents, we and others have previously demonstrated that engineered human and mouse stem cells home extensively to GBMs and have therapeutic benefits [11] [12] [13] [14] [15] .
There are several barriers to effectively testing stem cell-based therapeutic interventions in a mouse model of GBM resection, including developing methods to introduce stem cells into the resection cavity to prevent rapid 'washout' of a substantial number of cells by cerebrospinal fluid. Also, it is critical to allow efficient secretion of anti-GBM therapies and retain the ability of stem cells to migrate from the resection cavity into the parenchyma toward invasive tumor deposits. Biodegradable sECMs have been used in various rodent models owing to their ability to provide a physiologic environment that promotes stem cell survival while permitting easy in vivo transplantation and cell retention. In models of intracerebral hypoxia-ischemia and traumatic spinal cord injury, sECM acts as the necessary biomechanical substrate for endogenous neuroregeneration by increasing the viability of stem cells and promoting differentiation into neurons [16] [17] [18] . Subsequent studies again highlighted the utility of biodegradable scaffolds in facilitating stem cell-based therapy in the CNS 19, 20 . Although sECM are ideally suited for introducing therapeutic stem cells into GBM resection cavities, no studies have explored the therapeutic potential of this approach.
In this study we developed and tested sECM-encapsulated diagnostic and therapeutic mouse neural stem cells (NSCs) and human mesenchymal stem cells (MSCs) in culture and in vivo. Furthermore, we developed a method of introducing therapeutic stem cells into the resection cavity after GBM surgical debulking and showed the therapeutic efficacy of this approach in malignant and invasive GBM models. a r t I C l e S
RESULTS

Mouse model of GBM resection
To develop a mouse surgical resection model of GBM, we used malignant GBM cells engineered with fluorescent and bioluminescent proteins. Human U87 GBM cells were transduced with lentiviral (LV) construct LV-Fluc-mCherry, sorted and screened for mCherry fluorescent protein (Fig. 1a) and firefly luciferase (Fluc) expression (Fig. 1b) . There was a direct correlation between the Fluc expression and the number of cells (Fig. 1b) . We then implanted U87-Fluc-mCherry human GBM cells in a cranial window created by removal of a small circular portion of the skull (Fig. 1c,d ; Supplementary Fig. 1a,b) and imaged mice for tumor progression and volume over time by fluorescence intravital microscopy (IVM) and Fluc bioluminescence imaging. We resected established GBM tumors in mice generated by implantation of low (7.5 × 10 4 ) and high (1.5 × 10 5 ) numbers of GBM cells and used and IVM and BLI imaging to determine the extent of resection (Fig. 1e-i) . Fluc imaging confirmed more than 60% of the tumor was resected in mice bearing small tumors, whereas more than 80% of the tumor was resected in mice with large tumors that were easier to visualize ( Fig. 1i;  Supplementary Fig. 1c ). High resolution IVM and hematoxylin and eosin staining further confirmed the efficiency of resection ( Fig. 1e-i) . Kaplan-Meier survival curves showed a significant increase in the survival of mice with resected tumors as compared to the mice with un-resected tumors generated after implanting both low and high numbers of tumor cells (Fig. 1j) .
Characterizing mouse NSCs encapsulated in sECM
To assess survival of NSC encapsulated in sECM in vitro, we engineered mouse NSCs (mNSCs) to express either GFP-Fluc or to GFP-Fluc plus a secretable Renilla luciferase marker, Ss-Rluc(o), using our previously developed diagnostic lentiviral vectors 21, 22 (Fig. 2a) . We confirmed a direct correlation between number of sECMencapsulated cells and Fluc activity and Ss-Rluc(o) activity in vitro (Supplementary Fig. 2 ). Both engineered mNSC types were encapsulated in sECM (Fig. 2b) , and there was a stable increase in both the cell proliferation (Fluc activity) and protein secretion (Rluc activity) when mNSCs expressing GFP-Fluc plus Ss-Rluc(o) and encapsulated in sECM were cultured over time (Fig. 2c) . To assess the influence of sECM on cell survival in vivo, we implanted mNSC-GFP-Fluc cells in suspension or encapsulated in sECM intracranially and imaged mice serially for mNSC survival by Fluc activity. There was a significantly greater in vivo cell viability of sECM-encapsulated mNSCs as compared to the un-encapsulated mNSCs (Fig. 2d) . To longitudinally monitor mNSC-expressed proteins in vivo, we intracranially implanted sECM-encapsulated mNSCs expressing GFP-Fluc plus Ss-Rluc(o) in mice. In vivo, dual bioluminescence imaging showed a stable expression of Ss-Rluc(o) from mNSCs over time (Fig. 2e) . To follow migration of sECM-encapsulated mNSCs, we implanted mice bearing U87-Fluc-mCherry GBMs in a cranial window with mNSC-GFP-Rluc cells encapsulated in sECM 1 mm away from the established tumor. IVM revealed that sECM-encapsulated mNSCs migrated out of the sECM and specifically homed to tumors in the brain over a period of 4 d (Fig. 2f-i) .
To assess the therapeutic potential of mNSCs expressing therapeutic proteins that specifically kill tumor cells, we engineered mNSCs to express S-TRAIL or its diagnostic variant Di-S-TRAIL or controls. TRAIL is a cytotoxic agent that is known to induce apoptosis in about 50% of GBM 23, 24 . We showed a similar response of established and primary GBM lines to S-TRAIL-mediated apoptosis in vitro Fig. 3 ). There was a significant reduction in GBM cell viability when mNSC-S-TRAIL cells encapsulated in sECM were placed in the culture dish containing the TRAIL-sensitive human GBM cells U87-Fluc-mCherry ( Fig. 3a-e) . The decrease in GBM cell viability was associated with an increase in caspase-3/7 activity ( Fig. 3e) and changes in caspase-8 and polyADP-ribose polymerase (PARP) activity ( Fig. 3f; Supplementary Fig. 4 ). S-TRAIL ELISA confirmed a high TRAIL concentration (150-650 ng ml -1 ) in the culture medium containing mNSC-S-TRAIL cells encapsulated in sECM (Supplementary Fig. 5 ). To simultaneously monitor release of S-TRAIL from sECM-encapsulated mNSCs and its effect on GBM cell viability in sECM-encapsulated mNSCs cultured with U87-mCherryFluc GBM cells, we engineered mNSCs with Di-S-TRAIL. Dual bioluminescence imaging showed robust levels of Di-S-TRAIL released from sECM that increased as the stem cell/tumor cell ratio increased and resulted in a significant and dose-dependent decrease in GBM cell viability (Fig. 3g) . These results show that sECM-encapsulated engineered mNSCs survive longer in mice brains, migrate to tumors in the brain and induce apoptosis in cultured GBM cells.
Therapeutic effect of 'armed' stem cells in vivo
To assess survival of mNSCs encapsulated in sECM in mouse model of GBM resection, we implanted mNSC-GFP-Fluc cells, either in suspension or encapsulated, in the resection cavity of U87 GBMs. sECMencapsulated mNSCs were retained in the tumor resection cavity ( Fig. 4a-c ) at high local concentrations adjacent to the residual tumor cells (Fig. 4d) . sECM-encapsulated mNSC survival in the tumor resection cavity over a period of 1 month was significantly higher than that of the unencapsulated mNSCs in the resection cavity (Fig. 4e) . Next, to assess the therapeutic potential of sECM-encapsulated mNSC-S-TRAIL cells in mouse resection models of GBM, we implanted sECM-encapsulated mNSC-S-TRAIL or mNSC-GFP-Rluc cells intracranially in the tumor resection cavity and followed mice for changes in tumor volume by serial Fluc bioluminescence imaging and for survival. sECM-encapsulated mNSC-S-TRAIL cells induced a marked increase in caspase-3/7 activity and a >80% decrease in residual tumor cells as early as 3 d after seeding that could be followed by simultaneously visualizing caspase-3/7 activation and tumor volumes serially in vivo (Fig. 4f) . Notably, sECM-encapsulated mNSC-S-TRAIL cells suppressed regrowth of residual tumor cells through 49 d after resection (Supplementary Fig. 6 ). Highlighting the survival benefit of this approach, mice treated with control sECMencapsulated mNSC-GFP-Rluc cells showed a median survival of 14.5 d after GBM resection. In contrast, 100% of mice treated with mNSC-S-TRAIL cells encapsulated in sECM after GBM resection were alive 42 d after treatment (Fig. 4g) . sECM encapsulation was required for the survival benefit, as mNSC-S-TRAIL cells delivered in suspension into the resection cavity conferred no significant increase in survival ( Fig. 4g) . These results reveal that sECM-encapsulated therapeutic mNSCs are retained in the tumor resection cavity, kill residual GBM cells and thus result in significantly increased survival of mice. Several studies have shown that freshly isolated primary glioma lines from clinical specimens more accurately recapitulate the clinical scenario of GBMs. To assess the clinical relevance of sECM-encapsulated stem cell-based therapeutic regimen in a more clinically relevant model, we used a TRAIL-sensitive primary human invasive glioma line, GBM8, and human bone marrow-derived MSCs (hMSCs). We engineered GBM8 cells to express a mCherry-Fluc fusion protein and showed that the GBM8-mCherry-Fluc line retained the tumor cell invasive properties of the parental line in culture ( Fig. 5a ) and in vivo (Fig. 5b) . There was a direct correlation between the Fluc signal intensity and the number of cells in vitro in the ranges tested ( Supplementary Fig. 7 ). To assess the migration and the therapeutic potential of hMSCs expressing therapeutic proteins that specifically kill tumor cells, we engineered hMSCs to express GFP or S-TRAIL and GFP. In cultures of sECM-encapsulated hMSCs with GBM8 cells, hMSCs expressing GFP only or S-TRAIL migrated out of the sECM and tracked GBM8 cells (Fig. 5c-f) . Furthermore, hMSC-S-TRAIL (Fig. 5g ) and caspase-3/7-dependent (2.7 ± 0.1 fold increase in caspase-3/7 activity in comparison to hMSC-GFP cells) manner. Next, to assess the therapeutic potential of sECM-encapsulated hMSC-S-TRAIL cells in mouse resection models of primary GBM8 tumors, we implanted sECMencapsulated hMSC-S-TRAIL or hMSC-GFP cells intracranially in a GBM8 tumor resection cavity and followed mice for changes in tumor volume by serial Fluc bioluminescence imaging. The presence of sECM-encapsulated hMSC-S-TRAIL cells resulted in significantly less residual GBM8 cells than in the controls (Fig. 5h) . Fluorescence imaging of brain sections revealed the presence of encapsulated hMSCs in the tumor resection cavity and also suggested hMSCs migration to invading glioma cells (Fig. 5i,j) . Histopathological analysis on brain sections revealed a significantly higher number of cleaved caspase-3-positive cells in hMSC-S-TRAIL-treated mice than in controls ( Fig. 5k,l; 4.2 ± 0.2 fold increase in the hMSC-S-TRAIL group versus the hMSC-GFP group). These results show that sECMencapsulated engineered human MSCs have therapeutic benefits against primary tumor-derived GBMs.
DISCUSSION
In this study we tested diagnostic and therapeutic stem cells encapsulated in sECM in a mouse model of GBM resection. We show that sECM encapsulation of stem cells significantly increased their retention time in the GBM resection cavity, permitted robust tumorselective migration and allowed secretion of anti-tumor proteins from sECM-encapsulated stem cells in vivo. Furthermore, we show that TRAIL-secreting sECM-encapsulated stem cells transplanted in the resection cavity significantly delayed tumor regrowth in mice bearing established (U87) and primary invasive (GBM8) GBMs and significantly increased survival of mice bearing established GBMs. The clinical standard of care for patients suffering from GBMs includes surgical debulking 3, 6 , yet nearly all preclinical models focus on treating established solid tumors. Previously, a few studies have shown the feasibility of resecting established GBMs in different animal models 25, 26 . In this study, we expanded the results of previous studies by integrating fluorescent and bioluminescent markers and extensive optical imaging to simultaneously confirm the presence of established tumors, visualize the extent of tumor resection and serially monitor tumor regrowth after resection. The inclusion of post-resection bioluminescence imaging permitted gross assessment of total tumor removal, and real-time fluorescence microscopy permitted visualization of residual tumor cells and associated blood vessels in resected tumors. The combination of quantitative, noninvasive imaging and GBM resection should allow continued optimization of the resection model and further the exploration of anti-GBM therapeutics using mouse models with greater clinical relevance than current xenograft models that are focused on treating solid tumor masses.
Despite extensive preclinical evidence demonstrating the potential of cell-based therapy for GBM, no preclinical studies have explored methods to introduce therapeutically 'armed' stem cells in GBM resection cavities. The exploration of such methods is npg a r t I C l e S vital to prevent stem cell 'washout' and rapid diffusion from the resection cavity by cerebrospinal fluid while allowing release of anti-tumor proteins directly into the resection cavity from the transplanted stem cells. Biodegradable sECM formulations are an attractive approach for retention of stem cells in the resection cavity. Several previous studies have shown that biodegradable sECM increase the viability of mNSCs and their differentiation into neurons in vitro 16 . Recent in vivo studies suggest considerable potential for transplanted biodegradable scaffolds containing stem (and other neuronal) cells in models of degeneration and hypoxia-ischemia 27 . In this study we have used sECMs that are based on a thiol-modified hyaluronic acid and a thiol reactive cross-linker (polyethylene glycol diacrylate), which provides biocompatibility, physiological relevance and customizability 28 . Additionally, release profiles of sECM used in this study were well suited to permit both migratory stem cells and secreted therapeutic proteins to exit the sECM. These events were confirmed by serial monitoring of diagnostic markers (luciferase and fluorescence), which revealed that mNSCs migrated extensively out of the sECM toward GBM while secreting high levels of diagnostic proteins. We also observed that sECM encapsulation markedly increased the survival of mNSCs in resection cavities as compared to non-sECM-encapsulated cells over a period of 4 weeks. Although the precise reason for the increased survival of sECM-encapsulated mNSCs is unclear, studies have demonstrated that sECM encapsulation can enhance survival of transplanted cells by providing a physiologically relevant environment that promotes attachment to reduce anoikis-mediated death, reduce cell diffusion, and provide protection from the host immune system 29, 30 . Our study clearly reveals that sECM-encapsulated engineered mNSCs are effective at extending the drug exposure time of tumor cells, by means of retaining high concentrations of therapeutic stem cells at the site of tumor resection.
In our previous studies, we have shown that human NSCs have significantly shorter survival after implantation than mouse NSCs in nude mice bearing intracranial tumors 22 . As long-term survival of stem cells in mouse brains was critical for fully evaluating the therapeutic effects of encapsulated therapeutic NSCs, therefore we used primary mouse NSCs as opposed to human NSCs for most of our studies.
The ability of TRAIL to selectively target tumor cells while remaining harmless to most normal cells 10, 23, 24, 31 makes it an attractive candidate for an apoptotic therapy for highly malignant GBMs. Sustained levels of TRAIL are key to improving the efficiency and potency of TRAIL-based proapoptotic cancer therapy, and several studies have previously demonstrated that TRAIL-expressing human and mouse stem cells have therapeutic benefits [11] [12] [13] [14] [15] 32 . In our recent studies, we have shown that mNSCs do not express TRAIL receptors and are insensitive to TRAIL-mediated apoptosis 33 . Using a diagnostic variant of S-TRAIL, our results clearly reveal that mNSC-secreted S-TRAIL is released from sECM and induces caspase-3-mediated apoptosis in GBM cells in vitro. When encapsulated into sECM and implanted into resected GBM tumors, mNSC-S-TRAIL cells resulted in a significant increase in survival of mice bearing GBMs. These results confirm that TRAIL is a potent inhibitor of brain tumor growth and that encapsulated mNSC-S-TRAIL cytotoxic therapy is highly efficient in inducing apoptosis in residual GBM cells in our mouse model of GBM resection. Furthermore, stem cells have the advantage of offering a continuous and concentrated local delivery of secretable therapeutic molecules like TRAIL, thus reducing the nonselective targeting and allowing higher treatment efficiency and potency for a longer time period.
Although TRAIL is a selective and potent anti-tumor agent, many tumor lines, including some established GBM lines, have varying resistance or sensitivity to TRAIL-induced apoptosis, with about 50% of already established GBM lines being resistant to TRAIL 23, 24 (also see Supplementary Fig. 3 ). Although therapy with sECM-encapsulated TRAIL-secreting stem cells will be efficacious for TRAIL-sensitive 
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GBMs, many GBM tumors are likely to be fully resistant to TRAIL-based therapies. To address GBMs that are fully resistant to TRAIL, many in vitro studies have shown the potential of sensitizing TRAILresistant GBM cell lines to TRAIL-mediated apoptosis by treatment with agents including temozolomide 21 , protease inhibitors 34 , cisplatin 35 , proteasome inhibitors 36 and daidzein 37 . Recent in vivo studies have shown that treatment with irradiation followed by TRAIL-secreting umbilical cord blood-derived MSCs synergistically enhances apoptosis in TRAIL-sensitive and TRAIL-resistant GBM 38 . Although these studies hold promise, it would be ideal to use stem cells that simultaneously secrete different therapeutic proteins that target multiple pathways in GBMs as the only source of therapy. Along these lines, we have engineered stem cells to secrete an antiangiogenic agent consisting of three type-1 anti-angiogenic repeats of thrombospondin-1 (aaTSP-1) and shown in a recently published study that prolonged release of aaTSP-1 from stem cells in mice bearing gliomas targets GBM-associated vasculature and increases mouse survival 39 . As TSP-1 is known to normalize vasculature and upregulate death receptors DR4 and DR5 on tumor associated endothelial cells 40 , the use of stem cells expressing TRAIL and TSP-1 offers the potential to augment TRAIL-mediated apoptosis in both GBM cells and associated endothelial cells. We anticipate that the continued development of new stem cell-delivered, targeted anti-tumor agents and the use of systemically delivered sensitizing agents with stem cell-delivered TRAIL might ultimately allow treatment of both TRAIL-resistant and TRAIL-sensitive GBM tumor types.
The limited availability of noninvasive methods to monitor multiple molecular events has been one of the main limitations in testing the efficacy of various tumor therapy protocols. In our previous studies, we have shown that we can follow delivery of NSCs 22 and MSCs 32 and quantify GBM burden in vivo 22, 41 using noninvasive bioluminescence imaging. Combining bioluminescence imaging and confocal IVM offers great potential to image events serially. In this study, we have labeled tumor cells and stem cells with bimodal imaging markers (bioluminescent and fluorescent) expressed as a single transcript, which expands the number of events that can be visualized in vivo, and efficiently applied bioluminescence imaging to follow both un-resected and resected intracranial tumors and the fate of NSCs in vivo. To follow pharmacokinetics of therapeutic S-TRAIL both in culture and in mouse models of GBM, we have also used a C-terminal fusion of S-TRAIL with Ss-Rluc(o), which we recently engineered and characterized for its extracellular functionality 33 . In addition, we have also used a blood-pool agent, AngioSense-750, to visualize the tumor-associated vasculature. The inclusion of noninvasive molecular imaging allows characterization of multiple events in sECM-stem cell therapy with enhanced spatial and temporal resolution. Although the optical imaging methods used in this study are ideally suited for preclinical studies, further studies validating this approach incorporating clinical imaging modalities such as MRI will ease the translation of our approach to the clinic.
In recent years, primary GBM lines have been created from isolated human brain tumor tissue and used for preclinical studies. npg a r t I C l e S Several studies have shown that xenografts of these primary cell lines often recapitulate clinical GBM more faithfully than established GBM cell lines, thus providing more insights and a more stringent test of promising new anti-GBM therapies 42, 43 . In developing this study, we initially used an established glioma line, U87, that our laboratory and others have extensively characterized for in vivo tumor formation and assessment of target therapeutics in mouse models of brain tumors 21, 32, [41] [42] [43] [44] . Most of the established glioma lines, including U87, form solid intracranial tumors in most cases. This was essential for resection of the primary mass and for study of the effect of sECMencapsulated mouse stem cells on the residual tumor cells after resection. However, to test the efficacy of sECM-encapsulated stem cell therapy in mouse models of GBM that recapitulate all the features of the human cancer, we used the primary cell line GBM8. We and others have shown GBM8 cells form highly invasive tumors upon intracerebral implantation into mice 32 , thus recapitulating most of the features of human GBM. Although primary invasive lines are potentially more predictive, they introduce the technical difficulty of resecting invasive tumor cells from the brain. To circumvent this, we implanted ten times as many GBM8-mCherry-Fluc cells as used by us in previous reports 43 to create an initial solid tumor mass which could then be resected. In addition to a more clinically relevant tumor model, we also used bone marrow-derived hMSCs that have been extensively used in past and ongoing clinical trials (reviewed in ref. 15 ) and offer the potential of autologous transplantation, thus overcoming the limitation of immune rejection. Pairing the clinically relevant GBM and hMSC lines allowed us to perform extensive studies investigating the effect of encapsulated therapeutic hMSCs in invasive mouse model of GBM resection. Our results clearly showed that hMSC-S-TRAIL cells rapidly attenuated progression of GBM8 tumors in the brains of mice. Because of the clinical relevance of the models used in our study, our approach could be effective for treating patients suffering from GBM. However before translating these therapies to GBM patients, it is critical to use the most appropriate stem cell source and also to assess the long-term fate of these cells 15, 45 .
Although most studies, including our previous studies in mouse models of GBM, have shown that human bone marrow-derived MSCs offer the potential of autologous transplantation and have antitumor therapeutic potential (reviewed in ref. 15) , some studies have suggested tumor-promoting properties in mouse tumor models 46, 47 and mass formation in an experimental autoimmune encephalomyelitis model in mice 48 . As the tumorigenic potential of different stem cell types remains a potential concern, the use of alternative stem cell sources, including adipose tissue-derived MSCs 49 and skin-derived reprogrammed induced pluripotent NSCs (reviewed in ref. 50 ) from patients, should be considered. Alternatively, the incorporation of suicide genes such as HSV-TK into therapeutic human stem cell types would ultimately allow the eradication of therapeutic stem cells after GBM treatment. These approaches should eliminate any potential for malignant neoplasm formation from stem cells and heighten their safety for clinical applications.
In conclusion, our studies reveal the fate and therapeutic efficacy of engineered and sECM-encapsulated mouse and human stem cells in a mouse model of GBM resection. Using this study as a template, advances can be made in the way stem cells can be engineered and used clinically in patients with GBM. We envisage that, after the neurosurgical removal of the main tumor mass, the patient's own reprogrammed cells or MSCs, therapeutically engineered with antitumor agent(s) that eradicate GBMs, will be encapsulated in sECM and implanted in the resection cavity of the tumor. These cells would result in the death of both residual and invasive tumor cells, with the ultimate goal of improving patient outcomes. This study could also facilitate translation of stem cell-based therapies for the treatment of many other brain pathologies.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website.
cranial window were imaged for Fluc activity on the day of resection (day 21 after tumor cell implantation) and divided into four groups (n = 8 in each group) by distributing mice of matching tumor sizes (indicated by the Fluc signal intensity) equally across all groups, and tumors were resected (n = 24) as described above. Mice were imaged for Fluc signal intensity immediately after resection. sECM-encapsulated mNSC-S-TRAIL (n = 8) or mNSC-GFP-Rluc cells (n = 8) or unencapsulated mNSC-S-TRAIL cells (n = 8) were placed in the tumor resection cavity and mice were followed for survival over time, as were un-resected controls (n = 8). Tumor volumes in the mNSC-S-TRAIL and mNSC-GFP-Rluc groups were imaged by Fluc bioluminescence imaging as described earlier 32 . To study the effect of therapeutic hMSC-S-TRAIL cells encapsulated in sECM in the primary invasive GBM8 resection model, mice (n = 14) bearing GBM8-mCherry-Fluc tumors in the cranial window were imaged for Fluc activity on the day of resection (day 7 after tumor cell implantation) and divided into two groups (n = 7 in each group) as described above. sECM-encapsulated hMSC-S-TRAIL (n = 7) or hMSC-GFP (n = 7) cells were placed in the tumor resection cavity and tumor volumes were imaged by Fluc bioluminescence imaging as described earlier 32 .
dual bioluminescence imaging in vivo. To simultaneously visualize survival of encapsulated mNSCs and release of Ss-Rluc(o), mNSCs expressing GFP-Fluc and Ss-Rluc(o) were implanted in the frontal lobe of nude mice (n = 6) as described above. For dual luciferase imaging 7, 14, 21 and 28 d after implantation, mice were injected with 100 µg of coelenterazine per mouse through the tail vein and imaged for Ss-Rluc(o) activity as described previously 32 . Eighteen hours later, when there was no residual coelenterazine-Rluc activity, mice were injected with 1 mg d-luciferin per mouse intraperitoneally and imaged for Fluc activity 5 min later as described above. Postprocessing and visualization were performed as described previously 32 . To simultaneously visualize tumor volumes and caspase-3/7 activity, mice bearing U87-mCherry-Fluc tumors were resected and implanted with encapsulated mNSC-TRAIL or mNSC-GFP-Rluc cells in the resection cavity. Tumor volumes were followed by imaging mice for Fluc activity as described above. For imaging apoptosis induced by S-TRAIL expression, mice were injected intraperitoneally with highly purified Caspase-Glo 3/7 reagent (5 mg in 150 µl DMSO) and imaged for caspase-3-dependent luciferase activity for 5 min after administration of the Caspase-Glo 3/7 reagent. Postprocessing and visualization were performed as described previously 33 . All images are the visible light image superimposed with bioluminescence images with a scale in photons min -1 cm -2 .
tissue processing. Mice bearing tumors in the cranial window or mice with resected tumors or mice with resected tumors and implanted with sECMencapsulated mNSCs or hMSCs were perfused with formalin and brains were removed and sectioned. Cleaved caspase-3 immunohistochemical staining on brain sections was performed as described earlier 32 . Photomicrographs of immunohistochemistry and hematoxylin and eosin slides were taken using a Nikon E400 light microscope attached to a SPOT CCD digital camera (Diagnostics Instruments).
Statistical analysis. Data were analyzed by Student t-test when comparing two groups and by ANOVA, followed by Dunnett's post-test, when comparing more than two groups. Data are expressed as mean ± s.e.m., and differences were considered significant at P < 0.05. Survival times of groups of mice were compared using a log-rank test.
npg
